Disease Diagnosis TRIZ Cases

An automated evaluation system compares monocyte volume standard deviation and white blood cell count against specific thresholds to identify sepsis status.

Measuring GPC3-positive exosome levels diagnoses hepatocellular carcinoma with higher sensitivity than alpha-fetoprotein testing.

Segmenting blood proteome into organ groups enables detection of low abundance disease markers hidden by high abundance proteins.

Mitoferrofluor anchors to mitochondrial proteins via covalent bonds, enabling reliable iron detection when membrane potential collapses.

Multi-marker biomarker panel detects altered molecular levels to predict cardiotoxicity during drug development.

A lateral flow assay strip detects amniotic fluid proteins using monoclonal and polyclonal antibodies.

Combining catecholamine measurements via capillary electrophoresis resolves low sensitivity and specificity in early Alzheimer's disease detection.

Allogeneic leukemia-derived cell vaccine induces durable functional T cell responses to target residual cancer cells.

Procalcitonin concentration measurement in urine enables rapid urinary tract infection diagnosis, bypassing lengthy culture delays.

Surfactant and heat pretreatment separates thyroglobulin from interfering antibodies to improve immunoassay accuracy.

Measuring biochemical markers in red blood cell samples to assess post-transfusion survival and toxicity before transfusion.

Autoantibodies against aberrant peptides improve early-stage diagnosis reliability by bypassing low biomarker abundance constraints.

Extracting the midregional proadrenomedullin fragment reduces interference from binding proteins, ensuring reliable sepsis diagnosis.

NS1 protein immunoassay detects Zika-specific IgM and IgG antibodies, eliminating false positives from flavivirus cross-reactivity.

Analyzing circulating extracellular vesicles as surrogate indicators resolves the trade-off between invasive biopsy precision and patient convenience.

Segmenting detection into antiphospholipid screening and Borrelia confirmation resolves low sensitivity in early-stage Lyme disease diagnosis.

Segmenting breast epithelial cells by CD44 and CD24 expression overcomes the lack of reliable predictive markers for sporadic breast cancer.

Detecting CRELD2 and BiP proteins in urine samples enables early identification of endoplasmic reticulum stress.

A flexible display integrates M13 bacteriophage biosensors to detect volatile organic compounds through electrical resistance changes.

TG2-driven markers enable non-invasive endometriosis diagnosis, avoiding invasive laparoscopy risks while maintaining high sensitivity.

IL-8 levels monitor ERK inhibitor treatment effectiveness, replacing invasive tumor biopsies with simple venipuncture for accurate disease state assessment.

Iron oxide bead extraction concentrates prions from buffy coat cells, enabling real-time quaking-induced conversion detection despite low circulating levels.

Transient oxidant stress inducers trigger antioxidant protein expression to quantify patient reserve capacity.

Engineered monoclonal antibody binds phosphorylated tyrosine 1235 on MET protein for precise immunological detection.

Segmented biomarker panels using LSMEM2 antibodies resolve the contradiction between high-throughput isolation and subtype-specific identification accuracy.

A spectrophotometric assay calculates fetal hemoglobin by eluting adult variants from red blood cells in an acidic solution.

A measurement method uses a divalent-metal-ion-producing compound to form a phospholipid-containing complex for clotting time analysis.

Heme-induced complement activation assay identifies therapeutic compounds targeting sickle cell disease pathophysiology.

Multiplexed assay kit measures serum and urine biomarkers to evaluate treatment responses, enabling timely regimen adjustments that protect kidney function.

A method selects stents by measuring platelet coagulability levels against a defined threshold to guide implantation decisions.

A dual-mode sensor system combines Hall and TMR sensors to detect magnetic particles in blood samples.

Replacing subjective symptom rating scales, erythrocyte-derived extracellular vesicles provide objective quantification of Parkinson's disease progression.

Chemical synthesis of hydroxylated Ara h 2 mimotope peptides reduces diagnostic cost while maintaining measurement precision.

Effector-functionalized beads bind activated GTPases for multiplexed flow cytometry quantification, replacing labor-intensive Western blot methods.

Detecting cytolethal distending toxin antibodies enables specific irritable bowel syndrome identification.

Detecting free lyso-Gb1-sulfatide in plasma samples enables sensitive metachromatic leukodystrophy diagnosis.

Targeting toxic catecholamine syndrome, this approach uses beta-blockers to mitigate sympathetic hyperactivation and reduce early mortality in trauma or sepsis.

Diagnostic kit measures steroid resistance and Treg ratios to evaluate immune system functioning.

Inhibiting integrin alpha6 and GDNF pathways treats leptomeningeal disease metastases where standard chemotherapy fails to improve patient survival.

A lateral flow test strip captures oxLDL/β2GPI complexes using specific binding components and labeling agents.

Phospho-Scribble antibodies detect specific residues to classify triple-negative breast cancer prognosis without complex mass spectrometry.

A saliva diagnostic kit measures polymorphonuclear neutrophil levels to detect oral inflammation.

A lipoprotein cholesterol uptake assay uses labeled cholesterol and anti-ApoAI antibodies to form a measurable complex.

Switching from mRNA to serum GAPDH protein detection resolves reliability contradictions for accurate tumor monitoring.

Immobilized antigens capture antigen-specific immunocomplexes on a solid support for rapid biological analysis.

A biomarker signature combining complement factor Ba and soluble C5b9 enables precise detection of CM-TMA disease states.

Blocking CAMK1D caspase inhibition restores death receptor signaling, overcoming PD-L1 refractory tumor resistance.

Fluorescent dye quantification detects mitochondrial outer membrane permeabilization in viable leukemic cells to assess compound efficacy.

Antibodies detect MCL-1 and BIM heterodimers to overcome unreliable fluorescent signaling measurements.